Fortuna Mining Corp. Common Shares vs Medpace Holdings Inc — how do they compare? Fortuna Mining Corp. Common Shares trades at $10.89 (market cap $3.13B), while Medpace Holdings Inc trades at $602 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 5.4× Fortuna Mining Corp. Common Shares's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Fortuna Mining Corp. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortuna Mining Corp. Common Shares for 0 Days and Medpace Holdings Inc for 14 Days on average.
| FSM | MEDP | |
|---|---|---|
Market Cap | $3.13B | $16.82B |
Volume | 6,504,680 | 223,093 |
Sector | Basic Materials | Health |
52-Week High | $13.66 | $630.19 |
52-Week Low | $7.84 | $393.42 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $2.75B | $16.44B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Fortuna Mining is a Canadian precious-metals mining company with operations in Latin America and West Africa. It produces gold and silver and conducts exploration activities in several countries.
Read more on FSM →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →